Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2025-08-07 Capital/Financing Update
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically detailing the offering of common stock and pre-funded warrants. It includes detailed terms of the offering, underwriting information, risk factors, use of proceeds, and other related disclosures. This type of document is a capital markets filing related to fundraising activities and changes in capital structure. It is not a financial report, earnings release, management discussion, or any other type of report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not merely an announcement or a brief notice, supporting a high confidence classification.
2025-08-07 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock and pre-funded warrants, including pricing, underwriting, and use of proceeds. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion. It is clearly related to a financing activity and capital structure update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing.
2025-08-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 6, 2025. It contains preliminary unaudited financial information including estimated cash, cash equivalents, marketable securities, and impairment losses. It also discusses recent sales of common stock, clinical updates, and a personnel update. The document is not a full annual or quarterly report, nor is it an earnings release or a proxy statement. It is a regulatory filing used to report material events or updates outside of regular periodic reports. The length (over 10,000 characters) and content confirm it is a substantive report rather than a brief announcement. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2025-08-06 English
Regulatory Filings 2025
Regulatory Filings
2025-07-30 English
PRIMARY DOCUMENT
Director's Dealing
2025-07-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events or other material information that shareholders should know about between periodic reports. The text includes an announcement of positive clinical results and references a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is relatively short (3307 characters) and primarily serves to announce an event and furnish a press release. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-06-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.